Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

IBM Shares Face Pressure Despite Strong Software Performance

Felix Baarz by Felix Baarz
October 1, 2025
in AI & Quantum Computing, Earnings, Tech & Software, Turnaround
0
IBM Stock
0
SHARES
103
VIEWS
Share on FacebookShare on Twitter

IBM delivered a financial report that left investors with mixed emotions. While the technology giant demonstrated impressive strength in its software division and artificial intelligence business, concerning weaknesses emerged in consulting and infrastructure segments, sending shares tumbling in after-hours trading.

Financial Performance Reveals Diverging Trends

The third quarter painted a picture of two different companies within IBM. On one hand, the software unit delivered outstanding results with revenue climbing 10% to reach $6.52 billion, significantly outpacing analyst projections. The 2019 acquisition Red Hat proved particularly valuable, accelerating to 14% growth—double its pace from the previous quarter.

Software now represents nearly 45% of IBM’s total revenue and boasts an impressive gross margin of 83%, establishing itself as the corporation’s premium segment. CEO Arvind Krishna emphasized the division’s advantages, stating, “Our models are trustworthy, purpose-driven, and more cost-effective.”

However, the consulting business told a different story, stagnating at $5.15 billion and falling short of expectations. Corporate clients are reducing expenditures on shorter consulting engagements, directly impacting what has traditionally been one of IBM’s core strengths.

Infrastructure Challenges Offset AI Success

IBM’s artificial intelligence business exploded to $3 billion, representing an increase of over $1 billion from the prior quarter. Yet this remarkable growth couldn’t compensate for the dramatic downturn in infrastructure, where revenue declined 7% year-over-year to $3.04 billion, well below what market experts had anticipated.

Should investors sell immediately? Or is it worth buying IBM?

The primary culprit was a 19% plunge in IBM Z Mainframe sales, which CFO James Kavanaugh attributed to clients delaying purchases while awaiting the next generation system scheduled for 2025.

Balance Sheet Impact and Underlying Strength

IBM reported a net loss of $330 million, driven by a one-time pension provision of $2.7 billion. Beyond this special charge, the company’s adjusted earnings of $2.30 per share exceeded expectations by seven cents.

The cash flow statement revealed the organization’s fundamental resilience, with $6.59 billion generated over nine months—$1.5 billion more than the previous year. Management reaffirmed its target of exceeding $12 billion in total annual cash flow.

Market Reaction and Strategic Questions

Despite shares having advanced 43% since January began, investors responded to the quarterly results with a 6% after-market decline, erasing over $13 billion from IBM’s market capitalization. This reaction signals ongoing concerns about the company’s strategic direction.

While IBM’s artificial intelligence narrative remains compelling, structural issues in the consulting division continue to present challenges. The central question facing investors is whether the company’s software transformation can generate sufficient momentum to overcome weaknesses in other business areas.

Ad

IBM Stock: Buy or Sell?! New IBM Analysis from February 7 delivers the answer:

The latest IBM figures speak for themselves: Urgent action needed for IBM investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

IBM: Buy or sell? Read more here...

Tags: IBM
Felix Baarz

Felix Baarz

My name is Felix Baarz, and I look back on over fifteen years of experience as a business journalist. I have always been fascinated by the mechanisms and dynamics of global financial markets as well as the complex economic and political interconnections that shape our world. With this passion, I have made a name for myself as an expert on international financial markets and dedicate myself with great commitment to making even the most complex topics understandable and accessible to my readers. My roots lie in Cologne, where I was born and raised. Early on, my curiosity about economic topics and international developments sparked my interest in journalism. After completing my studies, I began my career as a business editor at a respected German trade publication. Here I laid the foundation for my professional career, but my curiosity soon drew me out into the wider world. A turning point in my life was moving to New York, where I lived for six years and gained insight into leading media houses. In this vibrant metropolis, I was able to report firsthand from the heart of the global financial world. From daily developments on Wall Street to major economic policy decisions that make waves worldwide, I had the opportunity to write about central topics that move people and markets alike. This time shaped my perspective and sharpened my view of global interconnections.

Related Posts

Allscripts Healthcare Stock
Analysis

Navigating a Pivotal Year: Veradigm’s Dual-Path Strategy for Stability and Growth

February 7, 2026
Avanos Medical Stock
Analysis

Avanos Medical’s Strategic Pivot: A Focus on High-Margin Growth

February 7, 2026
Yirendai Stock
AI & Quantum Computing

Yirendai Charts a New Course with Tech-Driven Strategy

February 7, 2026
Next Post
Universal Insurance Stock

Universal Insurance Shares Face Conflicting Technical Signals

Babcock & Wilcox Enterprises Stock

Market Skepticism Sinks Babcock & Wilcox Shares Despite Major Contract

Eli Lilly Stock

Pharmaceutical Giant Eli Lilly Surges on Government Pricing Talks

Recommended

Abbott Laboratories Stock

Can Abbott’s AI Innovation and Dividend Track Record Propel Its Shares?

3 weeks ago

Empowering the Next Generation enCore Energys Education Society and Scholarship Programs

2 years ago
Synopsys Stock

Synopsys Shares Face Critical Test Amid Legal and Analyst Concerns

2 months ago
Technology Blockchain Trading online

Applied Digital Corporation Announces Disappointing Financial Performance and Decline in Stock Price

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Guaranty Bancshares Sees Growth Accelerate Following Texas Expansion

Yirendai Charts a New Course with Tech-Driven Strategy

ServiceNow Shares Face Market Skepticism Despite Record Performance

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

A New Chapter for First Busey as CrossFirst Merger Finalizes

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Trending

Hbt Financial Stock
Analysis

HBT Financial Stock Surges as Strategic Acquisition Nears Completion

by Rodolfo Hanigan
February 7, 2026
0

Shares of HBT Financial have recently climbed to a new 52-week peak of $29.37, propelled by a...

Allscripts Healthcare Stock

Navigating a Pivotal Year: Veradigm’s Dual-Path Strategy for Stability and Growth

February 7, 2026
Avanos Medical Stock

Avanos Medical’s Strategic Pivot: A Focus on High-Margin Growth

February 7, 2026
Guaranty Bancshares Stock

Guaranty Bancshares Sees Growth Accelerate Following Texas Expansion

February 7, 2026
Yirendai Stock

Yirendai Charts a New Course with Tech-Driven Strategy

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • HBT Financial Stock Surges as Strategic Acquisition Nears Completion
  • Navigating a Pivotal Year: Veradigm’s Dual-Path Strategy for Stability and Growth
  • Avanos Medical’s Strategic Pivot: A Focus on High-Margin Growth

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com